10 / 49
Ongoing EGFR TKI Adjuvant Trials (in EGFRmut patient populations)
•
ALCHEMIST (US)
•
Erlotinib vs placebo x 2 years: N = 410
•
IMPACT WJOG6401L (Japan)
•
Gefitinib x 2 yrs vs Cisplatin/vinorelbine x 4 cycles N= 230
•
C-TONG 1104 Adjuvant Gefitinib Trial (China)
•
Gefitinib x 2 yrs vs Cisplatin/vinorelbine x 4 cycles, n=220
•
ADAURA (global): Osimertinib x 2 years vs placebo
•
Icotinib Studies (China)
•
AFTER 4 cycles adjuvant platinum chemo
Randomized to Icotinib vs Obs, N=477
•
NO prior adjuvant therapy
Randomized to Icotinib vs placebo, N= 300